Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Actavis Reveals Court Injunction On Generic Pulmicort RESPULES Distribution

RELATED NEWS
Trade ACT now with 

Actavis Inc. (ACT) Friday confirmed that the United States Court of Appeals for the Federal Circuit has granted a motion by AstraZeneca (AZN: Quote,AZN.L) to enjoin Actavis from further distribution of its generic version of AstraZeneca's Pulmicort RESPULES (budesonide inhalation suspension) 0.25, 0.5 mg products, pending resolution of AstraZeneca's appeal before the Court.

As a condition of the injunction, the Court has also ordered that AstraZeneca post a bond of $72 million.

Actavis launched its generic product on April 1, 2013, following a ruling from the U.S. District Court for the District of New Jersey that Actavis' 0.25, 0.5 and 1 mg generic version of Pulmicort RESPULES did not infringe United States Patent No. 7,524,834 and that United States Patent No. 6,598,603 was invalid.

On April 2, 2013, the District Court issued a temporary restraining order prohibiting sales of Actavis' generic product to permit AstraZeneca an opportunity to seek injunctive relief with the Federal Circuit.

Pulmicort RESPULES is a maintenance medicine used to control and prevent asthma symptoms in children ages 12 months to 8 years. For the 12 months ended January 31, 2013, total U.S. brand and generic sales of Pulmicort RESPULES were approximately $1.2 billion.

Register
To receive FREE breaking news email alerts for Actavis Plc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. said Tuesday after the markets closed that its third quarter profit rose 12% from last year, as sales surged and margins improved amid strong sales of its iPhones and Mac computers. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly sales fell short of analysts' forecast. United Nations Secretary-General Ban Ki-moon on Tuesday urged both Israelis and Palestinians to stop the fighting that has been raging for the past two weeks in the Gaza Strip, and pleaded with the two sides to return to dialogue with the aim of addressing the underlying causes of the repeated cycles... After moving notably higher in early trading on Tuesday, stocks continued to perform well throughout the session. The gains on the day offset the modest weakness that was seen in the previous session, extending the recent back-and-forth movement by the markets.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.